Kristen Hege

Independent Sector — United States

Medicine · Health Sciences

44h-index11.6kcitations163works1.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(59), Immunotherapy and Immune Responses(41), Cancer Immunotherapy and Biomarkers(29), Multiple Myeloma Research and Treatments(27), Protein Degradation and Inhibitors(23)

Publications163 total

Enabling access to genetically modified cell therapies through flexible approaches to manufacturing and cost recovery
Journal for ImmunoTherapy of Cancer·2025· 2 citedOpen Access
Going with the Flow: Circulating Tumor-Reactive Lymphocytes Stream into Cancer Therapy
Clinical Cancer Research·2025
Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma
Leukemia·2025· 3 citedOpen Access
Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial
Nature Medicine·2023· 106 citedOpen Access
S193: BMS-986393 (CC-95266), A G PROTEIN–COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D (GPRC5D)–TARGETED CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 1 STUDY
HemaSphere·2023· 15 citedOpen Access
Supplementary Figure 4 from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas
2023Open Access
Supplementary Figure 7 from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas
2023Open Access
Supplementary Figure 3 from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas
2023Open Access
Supplementary Data from Allogeneic Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation
2023Open Access
Supplementary Figure 2 from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas
2023Open Access
Supplementary Data from K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate
2023Open Access
Supplementary Figure 5 from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas
2023Open Access
Supplementary Figure 6 from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas
2023Open Access
Supplementary Figure 6 from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas
2023Open Access
Data from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas
2023Open Access
Supplementary Figure 4 from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas
2023Open Access
Data from K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate
2023Open Access
Data from Allogeneic Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation
2023Open Access
Supplementary Figure Legend from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas
2023Open Access
Supplementary Figure 7 from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas
2023Open Access
page 1 of 9Next →

Frequent Co-authors

Jesús G. Berdeja(13), Nikhil C. Munshi(12), Noopur Raje(12), David S. Siegel(12), Yi Lin(11), Fabio Petrocca(11), Sundar Jagannath(11), Timothy Campbell(9), Deepu Madduri(8), Monica Massaro(7), Michaela Liedtke(7), Ashley Turka(7), Nina Shah(6), Jacalyn Rosenblatt(6), Marcela V. Maus(6), James N. Kochenderfer(6), Carl H. June(6), John Nemunaitis(6), Michael R. Burgess(6), Steven G. Deeks(5)